Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all episode artwork

EPISODE · Nov 12, 2025 · 8 MIN

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all

from BiotechTV - News · host BiotechTV

CEO Mike Cloonan describes the unmet need for better treatments that exists today in CF, and discusses Sionna's development plans.

Episode metadata supplied by the publisher feed · Published Nov 12, 2025

Embed this episode

Ready to play

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all

0:00 8:36

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 8 minutes long.

When was this BiotechTV - News episode published?

This episode was published on November 12, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!